Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 1Gynecologic 1Endocrine 1

Conditions

Lymphoma 3Stomatitis 2Small Cell Lung Carcinoma 2Neoplasms 2Mucositis 2Mouth Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Small Cell 2Brain Neoplasms 2Spinal Cord Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 7Etoposide 6pembrolizumab 4Topotecan 4Pemetrexed 4Carboplatin 4Gemcitabine 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1atezolizumab 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × RRx-001 × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡